| Sign In to gain access to subscriptions and/or personal tools. |
No evidence for genetic association of interferon regulatory factor 3 in systemic lupus erythematosusInstituto de Parasitología y Biomedicina López-Neyra, CSIC, Granada, Spain
Servicio de Reumatología, Hospital Xeral-Calde, Lugo, Spain
Servicio de Medicina Interna, Hospital Clínico San Cecilio, Granada, Spain
Servicio de Medicina Interna, Hospital Clínico San Cecilio, Granada, Spain
Servicio de Medicina Interna, Hospital Virgen de las Nieves, Granada, Spain
Servicio de Medicina Interna, Hospital Virgen de las Nieves, Granada, Spain
Servicio de Medicina Interna, Hospital La Fe, Valencia, Spain
Departamento de Biología Funcional, Hospital Central de Asturias, Universidad de Oviedo, Oviedo, Spain
Departamento de Biología Funcional, Hospital Central de Asturias, Universidad de Oviedo, Oviedo, Spain
Servicio de Medicina Interna, Hospital Carlos-Haya, Malaga, Spain
Servicio de Medicina Interna, Hospital Carlos-Haya, Malaga, Spain
Servicio de Medicina Interna, Hospital Virgen de la Victoria, Malaga, Spain
Servicio de Medicina Interna, Hospital Parc Taulí, Sabadell, Spain
Servicio de Medicina Interna, Hospital Virgen de las Nieves, Granada, Spain
Servicio de Medicina Interna, Hospital Virgen del Rocío, Sevilla, Spain
Servicio de Medicina Interna, Hospital Virgen del Rocío, Sevilla, Spain
Servicio de Inmunología, Hospital Virgen del Rocío, Sevilla, Spain
Instituto de Parasitología y Biomedicina López-Neyra, CSIC, Granada, Spain The aim of this study was to determine the potential role of three IRF3 gene polymorphisms (rs2304204, rs7251 and rs2304207) with systemic lupus erythematosus (SLE). Our study population consisted of 610 patients with SLE and 730 healthy controls. All individual were of Spanish Caucasian origin. The IRF3 polymorphisms were genotyped using a PCR system with pre-developed TaqMan allelic discrimination assay. No statistically significant differences were found when allele and genotype distribution of rs2304204, rs7251 and rs2304207 polymorphisms were compared between patients with SLE and controls [overall P values: rs7251, P = 0.06; rs2304204, P = 0.26 and rs2304207, P = 0.36, by chi-squared test on a 3 x 2 contingency table. Overall allelic P values: rs7251, P = 0.8, OR (95%CI) = 1.03 (0.87–1.22); rs2304204, P = 0.2, OR (95%CI) = 1.12 (0.93–1.34) and rs2304207, P = 0.8, OR (95%CI) = 1.02 (0.82–1.26)]. In addition, no evidence of association with haplotypes and clinical features of SLE was found. Our data suggest that the IRF3 polymorphisms do not appear to play a major role in the susceptibility or severity of SLE in a Spanish population.
Key Words: autoimmune disease IRF3 polymorphisms susceptibility systemic lupus erythematosus
Lupus, Vol. 18, No. 3,
230-234 (2009) |
||||